ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Basal Insulin Adherence in Patients with Type 2 Diabetes Mellitus in Routine Clinical Practice in Spain: Clinical and Economic Impact.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes mellitus (T2DM) imposes a clinical and economic burden, largely due to its long-term micro- and macrovascular complications. To prevent these complications, treatment adherence is essential. The aim of this study was to analyse basal insulin adherence and its clinical and economic repercussions in patients with T2DM in Spain.
methodsRetrospective, descriptive observational study using the Spanish Health Improvement Network (THIN®) database. Adult patients with T2DM, a registry entry of first basal insulin prescription from January 2014, and prescription/dispensation records between January 2014 and January 2024 were included. Adherence was estimated as proportion of days covered ≥ 80% in patients with ≥ 1 (full-population) and ≥ 3 years of follow-up (≥ 3 years subpopulation). Sociodemographic, clinical characteristics, micro- and macrovascular complications incidence, healthcare resource use (HCRU) (outpatient general practitioner/nursing/specialists visits and laboratory tests), and sick leave were analysed in adherent and non-adherent patients of the ≥ 3 years subpopulation. Direct (complications + HCRU) and indirect costs were calculated.
resultsA total of 9441 patients in the full-population and 4693 in the ≥ 3 years subpopulation were included. Less than 70% were adherent (66.90% and 69.51%, respectively). Although adherent patients tended to be older and more were retired, sociodemographic and clinical characteristics were consistent in adherent and non-adherent patients. In both groups, 17-20% had micro- and 30-40% had macrovascular complications, but non-adherent patients showed increases of 5.54% and 15.90% in annual complications. Mean annual costs for micro- and/or macrovascular complications were €1091.68 for adherent and €1306.45 for non-adherent patients. Mean annual direct and indirect costs were €1528.45 and €784.97 in adherent and €1651.39 and €952.89 in non-adherent patients.
conclusionThis study shows less than 70% adherence to basal insulin under routine clinical practice in Spain and reveals unmet needs in current T2DM therapies. Non-adherence could result in more complications, which would lead to higher costs for the healthcare system.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.